高水平的血清补充3是接受托西利祖马布的TA患者血管狭窄进展的危险因素:一项前性观察性研究
Chen Rongyi1,2, Dai Xiaojuan1,2, Wang Jinghua1,2
1Department of Rheumatology, Zhongshan Hospital Fudan University, No.180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Arthritis research & therapy
|August 2, 2023
概括
托西利祖马布对塔卡亚苏动脉炎 (TA) 有效,但有些患者会出现静音血管狭窄症 (VSP) 的进展. 在这些患者中,高基线补充3 (C3) 水平是VSP的重要危险因素.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 血管医学 血管医学
背景情况:
- 托西利祖马布是一种IL-6R抗体,对塔卡亚苏动脉炎 (TA) 有效.
- 尽管接受了托西利祖马布治疗,但一些TA患者经历了静音血管狭窄症 (VSP) 的进展.
- 识别VSP的风险因素对于优化TA管理至关重要.
研究的目的:
- 调查与高雅苏动脉炎 (TA) 患者的血管狭窄进展 (VSP) 相关的风险因素,这些患者接受了托西利祖马布治疗.
- 在这个患者队列中确定VSP的预测因子.
主要方法:
- 对38名接受托西利祖马布治疗的TA患者进行前性队列研究.
- 血管狭窄进展 (VSP) 通过血管学 (MRA/CTA) 监测.
- 考克斯回归分析以确定VSP的风险因素.
主要成果:
- 在随访期间,18名患者 (47.4%) 发展出VSP.
- 在VSP患者中观察到更高的基线补充3 (C3) 水平.
- 基线C3水平 (HR=7.05) 是VSP的一个独立风险因素 (切断值1.22g/L).
结论:
- 血管狭窄进展 (VSP) 影响了 Takayasu 动脉炎 (TA) 接受托西利祖马布治疗的近一半患者.
- 基线补充3 (C3) 的升高是VSP的重要危险因素.
- 基线C3水平可以指导TA中托西利祖马布的治疗决策.
相关概念视频
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Coronary Artery Disease III: Clinical Manifestations
13
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
13
Rheumatic Heart Disease III: Medical Management
20
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
20
Mitral Stenosis III: Medical Management
13
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
13
Pericarditis III: Medical Management
15
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
15
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
38
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38


